Table 2.
Clinical sign and mycological findings of ACLF patients with IPA
| Whole cohort (n = 145) | |
|---|---|
| Signs and symptoms | |
| Refractory fever | 67 (46.2%) |
| Recrudescent fever | 36 (24.8%) |
| Pleuritic chest pain | 4 (2.8%) |
| Pleuritic rub | 15 (10.3%) |
| Dyspnea | 68 (46.9%) |
| Hemoptysis | 32 (22.1%) |
| Worsening respiratory insufficiency | 56 (38.6%) |
| Disseminated infection | 3 (2.1%) |
| Leukocyte count in 109/l, mean(SD) | 12.38 (7.40) |
| Neutrophils, mean (SD) | 80.00 (10.86) |
| Neutrophils count in 109/l, mean(SD) | 10.30 (6.78) |
| C-reactive protein in mg/l, mean(SD) | 35.75 (26.26) |
| Procalcitonin in ng/ml, median (interquartile range) | 1.08 [0.12,129.00] |
| Mycological findings, n (%) | |
| Direct test (cytology, direct microscopy, or culture) | 100 (69.0%) |
| Aspergillus fumigatus | 69 (69.0%) |
| Aspergillus flavus | 22 (22.0%) |
| Galactomannan antigen detected in plasma | 71 (49.0%) |
BW body weight, HBV hepatitis B virus, EASL-CLIF European Association for the Study of the Liver- Chronic Liver Failure consortium, SOFA sequential organ failure assessment score, Refractory fever fever refractory to at least 3 d of appropriate antibiotic therapy, Recrudescent fever recrudescent fever after a period of defervescence of at least 48 h while still on antibiotics and without other apparent cause, Worsening respiratory insufficiency worsening respiratory insufficiency in spite of appropriate antibiotic therapy and ventilatory support